News

News

Events

OncXerna Therapeutics Announces New Phase 2 and Biomarker Data in Gastric Cancer from Bavituximab Program at the ESMO Congress 2021

Waltham, MA. September 16, 2021 – Oncxerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapies, today announced new clinical and biomarker data from its bavituximab program in an electronic poster at the European Society of Medical Oncology (ESMO) Congress 2021.

QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements

Hilden, Germany, Waltham, MA., and Germantown MD, August 9, 2021 – QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced signing a master companion diagnostics (CDx) agreement to develop a NGS CDx for OncXerna’s product candidate, Navicixizumab, and a non-exclusive license to the Xerna™ TME panel.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Waltham, MA. July 19, 2021 – OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021. Please click the following link to register for the event: Register...

OncXerna Therapeutics to Present at Jefferies Virtual Healthcare Conference

Waltham, MA. May 18, 2021 – OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m. ET. A link to the live webcast...

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.